Drug patent expiration is an issue that many pharmaceutical companies face today. In this pharmaceutical case study, a mid-tier global pharma company approached L.E.K. Consulting with a looming revenue "cliff" due to impending exclusive drug patent expiration on some of their key products.

L.E.K.'s Marc Kozin and his team were tasked with transforming the company's business development culture, capabilities and strategy with the expectation that a revised external M&A and licensing strategy would mitigate its impending revenue gap and set the state for growth. In fewer than 18 months, L.E.K. worked with the company's management to execute more than a dozen deals, and they transformed themselves from a traditional pharma company into an industry leader with a strong and diverse pipeline, a solid portfolio for marketed products and a clear vision for the future.